|
Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program
|
26 September 2017 |
|
Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases
|
30 March 2017 |
|
Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme
|
12 October 2016 |
|
Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan
|
14 July 2016 |
|
Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment
|
25 February 2016 |
|
Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23
|
22 September 2015 |
|
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
|
17 April 2013 |
|
Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
|
01 November 2011 |
|
Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative
|
31 August 2011 |
|
Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System
|
05 July 2010 |
|
Ranbaxy Launches Antiplatelet Agent Prasugrel in India
|
10 June 2010 |
|
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effientâ¢
|
13 July 2009 |
|
DAIICHI SANKYO continues its expansion in Germany and Europe
|
21 August 2008 |
|
DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly
|
07 March 2008 |